Development of a novel prognostic score for 1-year survival in immunotherapy-treated patients with unresectable HCC: the ALIVE-IO score
The ALIVE-IO score is a promising tool for predicting 1-year OS in HCC patients undergoing immunotherapy using common laboratory, imaging and histological data frequently used in everyday clinical practice.
Authors
- Orestis Sidiropoulos
- Georgios C. Sotiropoulos (ORCID: https://orcid.org/0000-0003-3236-6579)
- Nikolaos Machairas (ORCID: https://orcid.org/0000-0003-3239-3905)
- Spyridon Pantzios (ORCID: https://orcid.org/0000-0003-3038-3084)
- Ioannis Elefsiniotis
- Evgenia Mainta (ORCID: https://orcid.org/0000-0003-1169-1727)
- Antonia Syriha
- Nikolaos Ptohis
- Dimitris P. Korkolis
- Ioannis Skouras
Institutions
- National and Kapodistrian University of Athens (GR)
- General Hospital of Athens G. Genimatas (GR)
- Hospital Agioi Anargyroi (GR)
- St Savas Hospital (GR)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-08-29
- DOI
- https://doi.org/10.3389/fimmu.2025.1648248
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00